

(204100)

Medical Benefit		Effective Date: 04/01/15	Next Review Date: 01/20
Preauthorization	No	Review Dates: 01/15, 01/16, 01/17, 01/18, 01/19	

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> With risk factors for cardiovascular disease 	Interventions of interest are: <ul style="list-style-type: none"> Cardiovascular risk panels 	Comparators of interest are: <ul style="list-style-type: none"> Management of clinical risk factors with or without simple lipid testing 	Relevant outcomes include: <ul style="list-style-type: none"> Test accuracy Test validity Other test performance measures Change in disease status Morbid events

DESCRIPTION

Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of cardiovascular disease (CVD). There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

SUMMARY OF EVIDENCE

For individuals who have risk factors for CVD who receive CVD risk panels, the evidence includes multiple cohort and case-control studies and systematic reviews of these studies. The relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, and morbid events. The available evidence from cohort and case-control studies indicates that many of the individual risk factors included in CVD risk panels are associated with increased risk of CVD. However, it is not clear how the results of individual risk factors impact management changes, so it is also uncertain how the panels will impact management decisions. Given the lack of evidence for clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CVD risk panels improves outcomes. Studies that have evaluated the clinical validity of panels of multiple markers have not assessed management changes that would occur as a result of testing or demonstrated improvements in outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels, see Policy Guidelines), are considered **investigational**.

POLICY GUIDELINES

A simple lipid panel is generally composed of the following lipid measures:

- Total cholesterol
- Low-density lipoprotein cholesterol
- High-density lipoprotein cholesterol
- Triglycerides

Certain calculated ratios, (e.g., total/high-density lipoprotein cholesterol) may also be reported as part of a simple lipid panel.

Other types of lipid testing (i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a)), are not considered components of a simple lipid profile.

This protocol does not address the use of panels of biomarkers in the diagnosis of acute myocardial infarction.

BACKGROUND

CARDIOVASCULAR DISEASE

CVD remains the single largest cause of morbidity and mortality in the developed world. As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

Risk Assessment

Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score.¹ The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins.

Many additional biomarkers, genetic factors, and radiologic measures have been associated with increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk.^{2,3,4} Some general categories of these potential risk factors are as follows:

- Lipid markers. In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- Inflammatory markers. Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.

- Metabolic syndrome biomarkers. Measures associated with metabolic syndrome, such as specific dyslipidemic profiles or serum insulin levels, have been associated with increased risk of CVD.
- Genetic markers. A number of variants associated with increased thrombosis risk, such as the MTHFR variant or the prothrombin gene variants, have been associated with increased CVD risk.
- Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

Risk Panel Testing

CVD risk panels may contain measures from one or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.

Some examples of commercially available CVD risk panels are as follows:

- CV Health Plus Genomics™ Panel (Genova Diagnostics): apolipoprotein (apo) E; prothrombin; factor V Leiden; fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; Lp(a); lipoprotein-associated phospholipase A2 (Lp-PLA2); MTHFR gene; triglycerides; very-low-density lipoprotein (VLDL); VLDL size; vitamin D; hs-CRP.
- CV Health Plus™ Panel (Genova Diagnostics): fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; lipid panel; Lp(a); Lp-PLA2; triglycerides; VLDL; VLDL size; vitamin D; hs-CRP.
- CVD Inflammatory Profile (Cleveland HeartLab): hs-CRP, urinary microalbumin, myeloperoxidase, Lp-PLA2, F2 isoprostanes.
- Applied Genetics Cardiac Panel: genetic variants associated with coronary artery disease: cytochrome p450 variants associated with metabolism of clopidogrel, ticagrelor, warfarin, β -blockers, rivaroxaban, prasugrel (2C19, 2C9/VKORC1, 2D6, 3A4/3A5), factor V Leiden, prothrombin gene, MTHFR gene, APOE gene.
- Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel: factor V Leiden, factor V R2, prothrombin gene, factor XIII, fibrinogen-455, plasminogen activator inhibitor-1 (PAI-1), platelet GP IIIA variant HPA-1 (PLA1/2), MTHFR gene, angiotensin converting enzyme insertion/deletion (ACE I/D), apo B, apo E.
- Cardiac-Related Test Panels (Singulex): Several panels of markers related to cardiac dysfunction, vascular inflammation and dysfunction, dyslipidemia, and cardiometabolic status are offered by Singulex. Some are offered in conjunction with a CVD testing and wellness management service. The test panels use an immunoassay method referred to as “ultra-sensitive Single Molecule Counting [SMC] technology.”⁵
 - Cardiac Dysfunction panel: SMC™ cTnI (high-sensitivity troponin), N-terminal pro-B-type natriuretic peptide.
 - Vascular Inflammation and Dysfunction panel: SMC™ IL-6, SMC™ IL-17A, SMC™ TNF α , SMC™ Endothelin, Lp-PLA2, hs-CRP, homocysteine, vitamin B12, folate.
 - Dyslipidemia panel: total cholesterol, LDL-C (direct), apo B, small dense LDL, HDL cholesterol, apo AI, HDL2b, triglycerides, Lp(a).
 - Cardiometabolic panel: parathyroid, vitamin D, calcium, magnesium, leptin, adiponectin, ferritin, cortisol, cystatin C, hemoglobin A1c, glucose, insulin, thyroid-stimulating hormone, T3 and free T4, uric acid, liver panel, renal panel, thyroid peroxidase antibody, thyroglobulin antibody.

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. Examples of these panels include:

- Cardiometabolic Panel (Singulex): described above.
- WellnessFX Premium (WellnessFX): total cholesterol, HDL, LDL, triglycerides, apo AI, apo B, Lp(a), Lp-PLA2, omega-3 fatty acids, free fatty acids, lipid particle numbers, lipid particle sizes, blood urea nitrogen/creatinine, aspartate aminotransferase and alanine aminotransferase, total bilirubin, albumin, total protein, dehydroepiandrosterone, free testosterone, total testosterone, estradiol, sex hormone binding globulin, cortisol, insulin-like growth factor 1, insulin, glucose, hemoglobin A1c, total T4, T3 uptake, free T4 index, thyroid-stimulating hormone, total T3, free T3, reverse T3, free T4, hs-CRP, fibrinogen, homocysteine, complete blood count with differential, calcium, electrolytes, bicarbonate, ferritin, total iron binding capacity, vitamin B12, red blood cell magnesium, 25-hydroxy vitamin D, progesterone, follicle-stimulating hormone, luteinizing hormone.⁶

REGULATORY STATUS

Multiple assay methods for cardiac risk marker components, such as lipid panels and other biochemical assays, have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process.

Other components of testing panels are laboratory-developed tests (LDTs). Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; LDTs must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer LDTs must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RELATED PROTOCOLS

Gene Expression Testing in the Evaluation of Patients With Stable Ischemic Heart Disease

Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease

Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. D'Agostino RB, Sr., Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. Jul 11 2001;286(2):180-187. PMID 11448281
2. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med*. Oct 6 2009;151(7):496-507. PMID 19805772
3. Brotman DJ, Walker E, Lauer MS, et al. In search of fewer independent risk factors. *Arch Intern Med*. Jan 24 2005;165(2):138-145. PMID 15668358
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Dec 14 2010;56(25):e50-103. PMID 21144964
5. Singulex. The Sgx Clarity System. 2015; <https://www.singulex.com/sgx-clarity-system/>. Accessed November 30, 2017.
6. WellnessFX. Premium: The Deluxe Deep Dive. n.d.; <https://www.wellnessfx.com/premium>. Accessed November 30, 2017.
7. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. *PLoS One*. May 2013;8(4):e62080. PMID 23630624
8. Gottlieb SS, Harris K, Todd J, et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. *Clin Biochem*. Mar 2015;48(4-5):292-296. PMID 25541019
9. Patterson CC, Blankenberg S, Ben-Shlomo Y, et al. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). *Int J Cardiol*. Dec 15 2015;201:113-118. PMID 26298350
10. Schoe A, Schippers EF, Ebmeyer S, et al. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest*. Nov 2014;146(5):1310-1318. PMID 24992322
11. Wuopio J, Hilden J, Bring C, et al. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. *Atherosclerosis*. Sep 15 2018;278:97-102. PMID 30261474
12. Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail*. Feb 2018;20(2):268-277. PMID 28960777
13. Harari G, Green MS, Magid A, et al. Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up. *Am J Cardiol*. Apr 15 2017;119(8):1193-1198. PMID 28267961
14. Kunutsor SK, Bakker SJ, James RW, et al. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. *Atherosclerosis*. Feb 2016;245:143-154. PMID 26724525
15. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. Jun 20 2012;307(23):2499-2506. PMID 22797450
16. Keller T, Boeckel JN, Gross S, et al. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. *Sci Rep*. Jul 03 2017;7(1):4511. PMID 28674420
17. de Lemos JA, Ayers CR, Levine B, et al. Multimodality strategy for cardiovascular risk assessment: performance in 2 population-based cohorts. *Circulation*. May 30 2017;135(22):2119-2132. PMID 28360032

18. Greisenegger S, Segal HC, Burgess AI, et al. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study. *Stroke*. Mar 2015;46(3):659-666. PMID 25649803
19. Cho S, Lee SH, Park S, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. *Acta Cardiol*. Apr 2015;70(2):205-210. PMID 26148381
20. Wilsgaard T, Mathiesen EB, Patwardhan A, et al. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromso Study. *Circ Cardiovasc Genet*. Apr 2015;8(2):363-371. PMID 25613532
21. Guarrera S, Fiorito G, Onland-Moret NC, et al. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics*. 2015;7:133. PMID 26705428
22. Lara J, Cooper R, Nissan J, et al. A proposed panel of biomarkers of healthy ageing. *BMC Med*. Sep 15 2015; 13:222. PMID 26373927
23. Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. *JAMA*. Feb 17 2010;303(7):631-637. PMID 20159871
24. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. Feb 14 2007;297(6):611-619. PMID 17299196
25. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. May 15 2008;358(20):2107-2116. PMID 18480203
26. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Jun 24 2014;129(25 Suppl 2):S49-73. PMID 24222018
27. U.S. Preventive Services Task Force. Coronary Heart Disease: Screening Using Non-Traditional Risk Factors. 2009; <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/coronary-heartdisease-screening-using-non-traditional-risk-factors>. Accessed November 30, 2017.